Cardiolipin Antibody (IgG): What a Positive aCL IgG Result Means

In one sentence

Cardiolipin IgG is an autoantibody against one of the body's own phospholipids, and a positive result is a prompt to confirm persistence and look at the clinical picture — not a diagnosis on its own.

At a Glance

• What it measures: IgG antibodies to cardiolipin, a phospholipid, reported in GPL units
• What it is: an autoantibody — one of the antiphospholipid antibodies
• Why it is ordered: evaluation of antiphospholipid syndrome, usually after an unexplained clot or a specific pregnancy complication, or in lupus
• The finding that matters: a positive result — but only when confirmed persistent and paired with a clinical event
• Read with: cardiolipin IgM, anti-β₂-glycoprotein I, and the lupus anticoagulant
• What it cannot do: diagnose APS on its own, or from a single positive result

What cardiolipin is, and what the antibody does

Cardiolipin is a phospholipid — a fat molecule that forms part of cell membranes. It is found throughout the body and is especially abundant in the inner mitochondrial membrane, the structures that power cells. It is a normal, essential component of healthy cells.

A cardiolipin antibody is an autoantibody: an antibody the immune system has mistakenly made against this normal self-component. That is the key to the whole test. This is not an antibody against an infection, and it is not an antibody against a clotting factor. It is the immune system targeting one of the body's own building blocks — and when antibodies like this are present and persistent, they are associated with a tendency to form abnormal blood clots.

This is worth stating plainly because the relationship is easy to get backwards. The phospholipid itself is not what causes clots. The antibodies against it are the marker of the clotting tendency, in the condition called antiphospholipid syndrome.

There is a further subtlety worth knowing. Although these are called cardiolipin antibodies, many of the clinically important ones are β₂-glycoprotein I-dependent: they recognize a blood protein, β₂-glycoprotein I, when it has bound to cardiolipin, rather than binding cardiolipin directly. Infection-associated cardiolipin antibodies are often β₂-glycoprotein I-independent and transient, while β₂-glycoprotein I-dependent antibodies are more strongly associated with APS. This is one reason cardiolipin and anti-β₂-glycoprotein I results are often interpreted together.

What antiphospholipid syndrome is

Antiphospholipid syndrome (APS) is an autoimmune disorder in which antiphospholipid antibodies — cardiolipin antibodies among them — are associated with a raised risk of blood clots in veins or arteries and with specific pregnancy complications, including recurrent pregnancy loss. Cardiolipin IgG is one of the antibodies used to evaluate it. APS is uncommon, which is one reason a positive antibody is interpreted cautiously rather than taken as a diagnosis from a single test.

APS is not diagnosed from an antibody result alone. It requires a clinical event together with a confirmed, persistent antibody, and modern classification criteria weigh several antibodies and clinical features together.

Reading your result

Cardiolipin IgG is reported in GPL units against a laboratory cutoff. Results are usually grouped into tiers, because the level carries clinical weight — but the exact boundaries are assay-specific.

These are Labcorp's result bands for test 161810 (GPL units). Cutoffs and tier boundaries differ between laboratories and assay platforms, so the bands printed on your own report are the ones that apply — a result of 18 is indeterminate on Labcorp's scale, for example, not positive. Separately, the international classification criteria for research (the 2023 ACR/EULAR system) weight standardized-ELISA values as moderate at 40–79 and high at ≥80; those are a research-classification scale, not a laboratory result band, and are not interchangeable with the reporting ranges above.

Why a positive result must be confirmed

A single positive cardiolipin IgG is not enough to mean anything lasting, because these antibodies are often temporary. They appear after infections — syphilis historically, but also common viral illnesses and mononucleosis — and after some medications, and then they fade. Transient antibodies of this kind generally do not carry the clotting risk that persistent ones do.

This is why confirmation is built into how the test is used: a positive result is repeated at least 12 weeks later, and only an antibody that is still present is treated as a durable finding. The 12-week interval reflects current criteria; some older guidance used a shorter six-week interval. Either way, the principle is the same — one positive is a prompt to recheck, not a conclusion.

Two people, same result

Person A has a low-medium positive result drawn shortly after an infection. Repeated at least 12 weeks later, it is negative — supporting a transient antibody rather than a persistent APS finding.

Person B has the same initial number, but it is still positive after 12 weeks. With an unexplained clot and positive companion antibodies, that same value is substantially more clinically important.

Same result, different meaning — decided by persistence, a clinical event, and the rest of the panel, not by the number.

What else causes a positive result

Cardiolipin IgG is not specific to APS. It also appears with:

• Infections — syphilis classically, and various viral infections and mononucleosis, usually transiently
• Systemic lupus erythematosus — the antibody is found in a substantial minority of people with lupus, and its presence is a marker of thrombosis risk in that setting
• Other autoimmune conditions and some malignancies
• Certain medications, which can induce the antibody
• Older age, where a low-level positive can appear without symptoms

Not all of these carry the same clotting risk, which is exactly why a positive result is interpreted with the clinical picture rather than as a standalone alarm.

Reading it alongside the other antiphospholipid antibodies

Cardiolipin IgG is rarely interpreted alone. The antiphospholipid workup tests several markers together, and the pattern across them — and how many are positive — carries more weight than any single result.

This table describes patterns clinicians commonly consider. It is not a diagnostic algorithm, and no row substitutes for a specialist's reading of your full picture.

Triple positivity = highest concern. When all three criteria antibodies are positive — cardiolipin, anti-β₂-glycoprotein I, and the lupus anticoagulant — the associated clotting risk is substantially higher than for any single positive result. If you have one positive, the most informative next question is what the other two are doing.

What this test cannot tell you

• Whether you have APS, from one result. Diagnosis needs persistence and a clinical event, not a single number.
• Whether a positive is transient or lasting. Only the 12-week repeat answers that.
• Your clotting risk in isolation. That comes from the full antibody pattern, especially how many are positive, plus your history.
• Anything from a low result. A negative is reassuring toward APS but is not a health problem in itself.

Common interpretation mistakes

• Reading a single positive as a diagnosis of APS. It is a prompt to confirm, not a conclusion.
• Thinking the phospholipid causes clots. The autoantibody is the marker; cardiolipin itself is a normal cell component.
• Comparing your number to a friend's from another lab. Cutoffs and platforms are not interchangeable.
• Treating a transient post-infection positive as APS. Many positives fade and never carry the risk.
• Reading a negative as ruling APS out entirely. Other antiphospholipid antibodies can still be positive.

Questions your doctor may ask

• Have you had an unexplained blood clot in a vein or artery?
• Any history of recurrent miscarriage or other specific pregnancy complications?
• Have you recently had an infection or started a new medication?
• Do you have lupus or another autoimmune condition?
• Have the other antiphospholipid antibodies — IgM, anti-β₂-glycoprotein I, lupus anticoagulant — been tested?
• Has this result been repeated to check whether it persists?

Read together with

• Cardiolipin IgM — the companion isotype; IgG generally carries more weight
• Anti-β₂-glycoprotein I (IgG and IgM) — a criteria antiphospholipid antibody
• Lupus anticoagulant — a functional clotting assay and a strong risk predictor
• A repeat cardiolipin IgG at ≥12 weeks — the confirmation that establishes persistence

Things that can affect the result

Recent infection or a new medication can produce a transient positive. The assay platform matters — ELISA and the newer automated methods report on scales that are not directly interchangeable, so results are read against the reporting lab's own cutoff. Anticoagulant treatment does not affect the cardiolipin immunoassay itself (though it does affect the separate lupus anticoagulant test). As with other immunoassays, sample quality can influence results.

Clinical pearls

• The antibody, not the phospholipid, is the marker of clotting risk — cardiolipin is a normal cell-membrane component.
• A single positive is never enough: persistence over 12 weeks plus a clinical event is what points toward APS.
• The IgG isotype and higher titers carry more weight; isolated low-level or IgM-only positives carry less.
• Triple positivity — cardiolipin, anti-β₂-glycoprotein I, and lupus anticoagulant all positive — carries substantially more risk than a single positive.
• Transient positives after infection are common and generally benign; this is the single most important reason not to over-read one result.

Clinical Takeaway

A positive cardiolipin IgG is a prompt, not a verdict. It has to be confirmed as persistent over 12 weeks and read alongside a clinical event and the rest of the antiphospholipid panel before it points to antiphospholipid syndrome — and a large share of positives, especially after infections, fade and never carry that meaning. A negative result is reassuring toward APS and is not a problem in itself. Bring the result to your clinician with the rest of the panel and your history.

If you remember only one thing: one positive cardiolipin IgG is a reason to recheck in 12 weeks, not a diagnosis — the antibody is common and often temporary, and it means the most when it is high, persistent, and paired with a clinical event.

Bottom line. This test measures an autoantibody against the body's own phospholipid. A positive result is worth taking seriously and confirming, but it is a starting point for evaluation, not an answer by itself.

This page is not medical advice. Reference cutoffs differ between laboratories and assay platforms, and only your own clinician can interpret your result in the context of your history, symptoms, and other findings.